{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:24:00Z","timestamp":1777350240526,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13104-016-1879-8","type":"journal-article","created":{"date-parts":[[2016,2,3]],"date-time":"2016-02-03T02:25:12Z","timestamp":1454466312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal"],"prefix":"10.1186","volume":"9","author":[{"given":"Sofia","family":"Vitor","sequence":"first","affiliation":[]},{"given":"Rui Tato","family":"Marinho","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"G\u00edria","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Velosa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,2,3]]},"reference":[{"key":"1879_CR1","first-page":"227","volume":"36","author":"KW Ray","year":"2002","unstructured":"Ray KW, Brown RS, Terrault NA, Hashem ES. Burden of liver disease in the United States: summary of a Workshop. Hepatology. 2002;36:227\u201342.","journal-title":"Hepatology"},{"key":"1879_CR2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3350\/kjhep.2011.17.4.274","volume":"17","author":"S Lee","year":"2011","unstructured":"Lee S, Woojin C, Kyung-Rae H. Socioeconomic costs of liver disease in Korea. Korean J Hepatol. 2011;17:274\u201391.","journal-title":"Korean J Hepatol"},{"key":"1879_CR3","doi-asserted-by":"crossref","first-page":"e7931","DOI":"10.1136\/bmj.e7931","volume":"345","author":"G Iacobucci","year":"2012","unstructured":"Iacobucci G. Liver disease rises in England while falling elsewhere in Europe, report says. BMJ. 2012;345:e7931.","journal-title":"BMJ"},{"key":"1879_CR4","unstructured":"Eurostat European social statistics 2013 edition. ( http:\/\/epp.eurostat.ec.europa.eu\/cache\/ITY_OFFPUB\/KS-FP-13-001\/EN\/KS-FP-13-001-EN.PDF )."},{"key":"1879_CR5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2012.04.015","volume":"57","author":"R Adam","year":"2012","unstructured":"Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European liver transplant registry (ELTR). J Hepatol. 2012;57:675\u201388.","journal-title":"J Hepatol"},{"key":"1879_CR6","unstructured":"Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe. European association for the study of the liver (EASL). ( http:\/\/www.easl.eu\/assets\/application\/files\/54ae845caec619f_file.pdf )."},{"key":"1879_CR7","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3748\/wjg.v13.i10.1522","volume":"13","author":"RT Marinho","year":"2007","unstructured":"Marinho RT, Giria J, Moura MC. Rising costs and hospital admissions for hepatocellular carcinoma in Portugal (1993\u20132005). World J. Gastroentero. 2007;13:1522\u20137.","journal-title":"World J. Gastroentero"},{"key":"1879_CR8","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1530-0277.2010.01229.x","volume":"34","author":"H Cortez-Pinto","year":"2010","unstructured":"Cortez-Pinto H, Gouveia M, dos Santos Pinheiro L, et al. The burden of disease and the cost of illness attributable to alcohol drinking-results of a national study. Alcohol Clin Exp Res. 2010;34:1442\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"1879_CR9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/00042737-200409000-00010","volume":"16","author":"H Cortez-Pinto","year":"2004","unstructured":"Cortez-Pinto H, Marques-Vidal P, Monteiro E. Liver disease-related admissions in Portugal: clinical and demographic pattern. Eur J Hepatol. 2004;16:873\u20137.","journal-title":"Eur J Hepatol"},{"key":"1879_CR10","unstructured":"European Association for the Study of the Liver Press Office. Chronic hepatic diseases generate high costs to Europe. Separate Study links acute-on-chronic liver failure to high short-term mortality. ( http:\/\/www.easl.eu\/assets\/application\/files\/f3263cb5942c12f_file.pdf )."},{"key":"1879_CR11","author":"LA Nader","year":"2014","unstructured":"Nader LA, de Mattos AA, Bastos GA. Burden of liver disease in Brazil. Liver Int. 2014;. doi: 10.1111\/liv.12470 .","journal-title":"Liver Int"},{"key":"1879_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1136\/tc.2008.027466","volume":"18","author":"RM John","year":"2009","unstructured":"John RM, Sung HY, Max W. Economic cost of tobacco use in India, 2004. Tob Control. 2009;18:138\u201343.","journal-title":"Tob Control"},{"key":"1879_CR13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000067730","volume":"9","author":"P Fenoglio","year":"2003","unstructured":"Fenoglio P, Parel V, Kopp P. The social cost of alcohol, tobacco and illicit drugs in France, 1997. Eur Addict Res. 2003;9:18\u201328.","journal-title":"Eur Addict Res"},{"key":"1879_CR14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5694\/j.1326-5377.2010.tb03503.x","volume":"192","author":"S Colagiuri","year":"2010","unstructured":"Colagiuri S, Lee CM, Colagiuri R, et al. The cost of overweight and obesity in Australia. Med J Aust. 2010;192:260\u20134.","journal-title":"Med J Aust"},{"key":"1879_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.socscimed.2010.10.026","volume":"72","author":"W Zhang","year":"2011","unstructured":"Zhang W, Bansback N, Anis AH. Measuring and valuing productivity loss due to poor health: a critical review. Soc Sci Med. 2011;72:185\u201392.","journal-title":"Soc Sci Med"},{"key":"1879_CR16","unstructured":"OECD Health Statistics 2014. Definitions, sources and methods. ( http:\/\/www.oecd.org\/health\/healthdata(2014) )."},{"key":"1879_CR17","unstructured":"CDC. Premature mortality in the United States: public health issues in the use of the years of potential life lost. ( http:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00001773.htm )."},{"key":"1879_CR18","unstructured":"Pordata. Taxa de actividade: total e por sexo (%). ( http:\/\/www.pordata.pt\/Portugal\/Taxa+de+actividade+total+e+por+sexo+(percentagem)-547 )."},{"key":"1879_CR19","unstructured":"Pordata. Taxa de actividade: total e por grupo et\u00e1rio (%). ( http:\/\/www.pordata.pt\/Portugal\/Taxa+de+actividade+total+e+por+grupo+etario+(percentagem)-1321 )."},{"key":"1879_CR20","unstructured":"Plano Nacional de Sa\u00fade 2012\u20132016. ( http:\/\/pns.dgs.pt\/nhp-in-english\/ )."},{"key":"1879_CR21","first-page":"61","volume":"25","author":"F George","year":"2012","unstructured":"George F. Causes of deaths in Portugal and challenges in prevention. Acta Med Port. 2012;25:61\u20133.","journal-title":"Acta Med Port"},{"key":"1879_CR22","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/acer.12331","volume":"38","author":"J Rehm","year":"2012","unstructured":"Rehm J, Dawson D, Frick U, et al. Burden of disease associated with alcohol use disorders in the United States. Alcohol Clin Exp Res. 2012;38:1068\u201377.","journal-title":"Alcohol Clin Exp Res"},{"issue":"9682","key":"1879_CR23","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(09)60744-3","volume":"373","author":"P Anderson","year":"2009","unstructured":"Anderson P, Chisholm D, Fuhr DC. Effectiveness and cost-effectiveness of policies and programmes to reduce the harm caused by alcohol. Lancet. 2009;373(9682):2234\u201346.","journal-title":"Lancet"},{"issue":"6","key":"1879_CR24","doi-asserted-by":"crossref","first-page":"782","DOI":"10.15288\/jsa.2004.65.782","volume":"65","author":"D Chisholm","year":"2004","unstructured":"Chisholm D, Rehm J, Van Ommeren M, Monteiro M. Reducing the global burden of hazardous alcohol use: a comparative cost-effectiveness analysis. J Stud Alcohol. 2004;65(6):782\u201393.","journal-title":"J Stud Alcohol"},{"key":"1879_CR25","volume-title":"The impact of alcohol advertising: ELSA project report on the evidence to strengthen regulation to protect young people","author":"P Anderson","year":"2007","unstructured":"Anderson P. The impact of alcohol advertising: ELSA project report on the evidence to strengthen regulation to protect young people. Utrecht: National foundation for alcohol prevention; 2007."},{"key":"1879_CR26","volume-title":"IARC Monographs on the evaluation of carcinogenic risks to humans (volume 59): Hepatitis viruses","author":"International Agency for Research on Cancer","year":"1994","unstructured":"International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans (volume 59): Hepatitis viruses. Lyon: IARC; 1994."},{"key":"1879_CR27","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(89)91015-5","volume":"2","author":"J Bruix","year":"1989","unstructured":"Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 1989;2:1004\u20136.","journal-title":"Lancet"},{"key":"1879_CR28","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958\u201365.","journal-title":"Lancet"},{"key":"1879_CR29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521\u201331.","journal-title":"N Engl J Med"},{"key":"1879_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1055\/s-0028-1110008","volume":"48","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Berg T, Ross RS, et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol. 2010;48:289\u2013351.","journal-title":"Z Gastroenterol"},{"key":"1879_CR31","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u201393.","journal-title":"JAMA"},{"key":"1879_CR32","unstructured":"International Agency for Research on Cancer. Cancer. Mondial. ( http:\/\/www-dep.iarc.fr )."},{"key":"1879_CR33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1586\/egh.09.35","volume":"3","author":"MI Shariff","year":"2012","unstructured":"Shariff MI, Cox IJ, Gomaa AI, et al. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol. 2012;3:353\u201367.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1879_CR34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","volume":"16","author":"J Chhatwal","year":"2013","unstructured":"Chhatwal J, Ferrante SA, Brass C, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health. 2013;16:973\u201386.","journal-title":"Value Health"},{"key":"1879_CR35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3111\/13696998.2013.860033","volume":"17","author":"S Cure","year":"2014","unstructured":"Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ. 2014;17:65\u201376.","journal-title":"J Med Econ"},{"key":"1879_CR36","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40273-013-0080-3","volume":"31","author":"A Bl\u00e1zquez-P\u00e9rez","year":"2013","unstructured":"Bl\u00e1zquez-P\u00e9rez A, SanMiguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics. 2013;31:919\u201331.","journal-title":"Pharmacoeconomics"},{"key":"1879_CR37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5501\/wjv.v1.i6.174","volume":"1","author":"LP Chen","year":"2012","unstructured":"Chen LP, Zhao J, Du Y, et al. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol. 2012;1:174\u201383.","journal-title":"World J Virol"},{"key":"1879_CR38","doi-asserted-by":"crossref","first-page":"g3308","DOI":"10.1136\/bmj.g3308","volume":"349","author":"ER Feeney","year":"2012","unstructured":"Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2012;349:g3308.","journal-title":"BMJ"},{"key":"1879_CR39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/jgh.12244","volume":"28","author":"JG Fan","year":"2012","unstructured":"Fan JG, Cao HX. Role of diet and nutritional management in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2012;28:81\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"1879_CR40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SGA.0b013e31825a2786","volume":"35","author":"JL McAfee","year":"2012","unstructured":"McAfee JL. Developing an advanced practice nurse-led liver clinic. Gastroenterol Nurs. 2012;35:215\u201324.","journal-title":"Gastroenterol Nurs"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-016-1879-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T03:52:55Z","timestamp":1718337175000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1756-0500\/9\/62"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,3]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1186\/s13104-016-1879-8","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,3]]},"article-number":"62"}}